Recent advances in diagnostics of neonatal hypoxic ischemic encephalopathy

Starodubtseva NL, Eldarov ChM, Kirtbaya AR, Balashova EN, Gryzunova AS, Ionov OV, Zubkov VV, Silachev DN
About authors

Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Moscow, Russia

Correspondence should be addressed: Denis N. Silachev
Akademika Oparina, 4, Moscow, 117997, Russia; ur.4anirapo@vehcalis_d

About paper

Funding: the study was supported by the Russian Science Foundation grant number 22-15-00454;

Author contribution: Starodubtseva NL, Eldarov ChM, Kirtbaya AR, Balashova EN, Gryzunova AS, Ionov OV, Zubkov VV and Silachev DN — literature analysis, manuscript writing and editing.

Received: 2022-07-06 Accepted: 2022-07-20 Published online: 2022-07-29

The prognosis in neonatal hypoxic ischemic encephalopathy (HIE) depends on early differential diagnosis for justified administration of emergency therapeutic hypothermia. The moment of therapy initiation directly affects the long-term neurological outcome: the earlier the commencement, the better the prognosis. This review analyzes recent advances in systems biology that facilitate early differential diagnosis of HIE as a pivotal complement to clinical indicators. We discuss the possibilities of clinical translation for proteomic, metabolomic and extracellular vesicle patterns characteristic of HIE and correlations with severity and prognosis. Identification and use of selective biomarkers of brain damage in neonates during the first hours of life is hindered by systemic effects of hypoxia. Chromatography– mass spectrometry blood tests allow analyzing hundreds and thousands of metabolites in a small biological sample to identify characteristic signatures of brain damage. Clinical use of advanced analytical techniques will facilitate the accurate and timely diagnosis of HIE for enhanced management.

Keywords: diagnostics, metabolomics, lipidomics, neonatal hypoxic ischemic encephalopathy, mass-spectrometry, proteomics